Literature DB >> 30305452

Long noncoding RNA lnc-TSI inhibits renal fibrogenesis by negatively regulating the TGF-β/Smad3 pathway.

Peng Wang1, Man-Li Luo2, Erwei Song2, Zhanmei Zhou1, Tongtong Ma1, Jun Wang1, Nan Jia1, Guobao Wang1, Sheng Nie1, Youhua Liu1, FanFan Hou3.   

Abstract

Transforming growth factor-β (TGF-β) is a well-established central mediator of renal fibrosis, a common outcome of almost all progressive chronic kidney diseases. Here, we identified a poorly conserved and kidney-enriched long noncoding RNA in TGF-β1-stimulated human tubular epithelial cells and fibrotic kidneys, which we termed TGF-β/Smad3-interacting long noncoding RNA (lnc-TSI). Lnc-TSI was transcriptionally regulated by Smad3 and specifically inhibited TGF-β-induced Smad3 phosphorylation and downstream profibrotic gene expression. Lnc-TSI acted by binding with the MH2 domain of Smad3, blocking the interaction of Smad3 with TGF-β receptor I independent of Smad7. Delivery of human lnc-TSI into unilateral ureteral obstruction (UUO) mice, a well-established model of renal fibrosis, inhibited phosphorylation of Smad3 in the kidney and attenuated renal fibrosis. In a cohort of 58 patients with biopsy-confirmed IgA nephropathy (IgAN), lnc-TSI renal expression negatively correlated with the renal fibrosis index (r = -0.56, P < 0.001) after adjusting for cofounders. In a longitudinal study, 32 IgAN patients with low expression of renal lnc-TSI at initial biopsy had more pronounced increases in their renal fibrosis index and experienced stronger declines in renal function at repeat biopsy at a mean of 48 months of follow-up. These data suggest that lnc-TSI reduced renal fibrogenesis through negative regulation of the TGF-β/Smad pathway.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30305452     DOI: 10.1126/scitranslmed.aat2039

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  51 in total

1.  CTRP1 Attenuates UUO-induced Renal Fibrosis via AMPK/NOX4 Pathway in Mice.

Authors:  Wen Li; Fan Cheng; Yi-Yan Songyang; Song-Yi-Sha Yang; Jie Wei; Yuan Ruan
Journal:  Curr Med Sci       Date:  2020-03-13

Review 2.  Emerging strategies to disrupt the central TGF-β axis in kidney fibrosis.

Authors:  Michael Rauchman; David Griggs
Journal:  Transl Res       Date:  2019-04-24       Impact factor: 7.012

Review 3.  Signaling pathways of chronic kidney diseases, implications for therapeutics.

Authors:  Qian Yuan; Ben Tang; Chun Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

4.  Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function: A Systematic Review and Meta-Analysis.

Authors:  Yan Zeng; Man Guo; Xia Fang; Fangyuan Teng; Xiaozhen Tan; Xinyue Li; Mei Wang; Yang Long; Yong Xu
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

Review 5.  Long Noncoding RNAs and Their Therapeutic Promise in Diabetic Nephropathy.

Authors:  Juan D Coellar; Jianyin Long; Farhad R Danesh
Journal:  Nephron       Date:  2021-04-14       Impact factor: 2.847

6.  Long non-coding RNA SMASR inhibits the EMT by negatively regulating TGF-β/Smad signaling pathway in lung cancer.

Authors:  Lele Xu; Wenzhong Liu; Tongtong Li; Yuying Hu; Yu Wang; Lijie Huang; Yan Wang; Shujuan Shao; Xuefeng Liu; Qimin Zhan
Journal:  Oncogene       Date:  2021-04-30       Impact factor: 9.867

Review 7.  Druggability of lipid metabolism modulation against renal fibrosis.

Authors:  Yuan-Yuan Chen; Xiao-Guang Chen; Sen Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

8.  A single-cell survey of the human glomerulonephritis.

Authors:  Zhejun Chen; Ting Zhang; Kaiqiong Mao; Xinghua Shao; Yao Xu; Minyan Zhu; Hang Zhou; Qin Wang; Zhenyuan Li; YuanYuan Xie; Xiaodong Yuan; Liang Ying; Ming Zhang; Jiajia Hu; Shan Mou
Journal:  J Cell Mol Med       Date:  2021-03-22       Impact factor: 5.310

Review 9.  TGFβ-Directed Therapeutics: 2020.

Authors:  Beverly A Teicher
Journal:  Pharmacol Ther       Date:  2020-08-21       Impact factor: 12.310

Review 10.  The Genomic Response to TGF-β1 Dictates Failed Repair and Progression of Fibrotic Disease in the Obstructed Kidney.

Authors:  Craig E Higgins; Jiaqi Tang; Stephen P Higgins; Cody C Gifford; Badar M Mian; David M Jones; Wenzheng Zhang; Angelica Costello; David J Conti; Rohan Samarakoon; Paul J Higgins
Journal:  Front Cell Dev Biol       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.